Extensively drug-resistant tuberculosis: New strains, new challenges

Ritu Banerjee; Gisela F. Schecter; Jennifer Flood; Travis C. Porco

doi:10.1586/14787210.6.5.713

Extensively drug-resistant tuberculosis: New strains, new challenges

Ritu Banerjee, Gisela F. Schecter, Jennifer Flood, Travis C. Porco

Pediatric and Adolescent Medicine

Research output: Contribution to journal › Review article › peer-review

32 Scopus citations

Abstract

Extensively drug-resistant (XDR)-TB, defined as TB with resistance to at least isoniazid, rifampin, a fluoroquinolone and either amikacin, kanamycin or capreomycin, is a stark setback for global TB control. Overburdened public-health systems with inadequate resources for case detection and management and high HIV coinfection rates in many regions have contributed to the emergence of XDR-TB. Patients with XDR-TB have poor outcomes, prolonged infectious periods and limited treatment options. To prevent an epidemic of untreatable XDR-TB, improvements in XDR-TB surveillance, increased laboratory capacity for rapid detection of drug-resistant strains, better infection control and the development of new therapeutics are urgently needed.

Original language	English (US)
Pages (from-to)	713-724
Number of pages	12
Journal	Expert Review of Anti-Infective Therapy
Volume	6
Issue number	5
DOIs	https://doi.org/10.1586/14787210.6.5.713
State	Published - Oct 2008

Keywords

Drug-susceptibility testing
Extensively drug-resistant tuberculosis
Multidrug-resistant tuberculosis
Second-line drug
Tuberculosis

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases
Virology
Microbiology

Access to Document

10.1586/14787210.6.5.713

Cite this

@article{ea8a792720d0457b8438131c1087cdda,

title = "Extensively drug-resistant tuberculosis: New strains, new challenges",

abstract = "Extensively drug-resistant (XDR)-TB, defined as TB with resistance to at least isoniazid, rifampin, a fluoroquinolone and either amikacin, kanamycin or capreomycin, is a stark setback for global TB control. Overburdened public-health systems with inadequate resources for case detection and management and high HIV coinfection rates in many regions have contributed to the emergence of XDR-TB. Patients with XDR-TB have poor outcomes, prolonged infectious periods and limited treatment options. To prevent an epidemic of untreatable XDR-TB, improvements in XDR-TB surveillance, increased laboratory capacity for rapid detection of drug-resistant strains, better infection control and the development of new therapeutics are urgently needed.",

keywords = "Drug-susceptibility testing, Extensively drug-resistant tuberculosis, Multidrug-resistant tuberculosis, Second-line drug, Tuberculosis",

author = "Ritu Banerjee and Schecter, {Gisela F.} and Jennifer Flood and Porco, {Travis C.}",

year = "2008",

month = oct,

doi = "10.1586/14787210.6.5.713",

language = "English (US)",

volume = "6",

pages = "713--724",

journal = "Expert Review of Anti-Infective Therapy",

issn = "1478-7210",

publisher = "Expert Reviews Ltd.",

number = "5",

}

TY - JOUR

T1 - Extensively drug-resistant tuberculosis

T2 - New strains, new challenges

AU - Banerjee, Ritu

AU - Schecter, Gisela F.

AU - Flood, Jennifer

AU - Porco, Travis C.

PY - 2008/10

Y1 - 2008/10

N2 - Extensively drug-resistant (XDR)-TB, defined as TB with resistance to at least isoniazid, rifampin, a fluoroquinolone and either amikacin, kanamycin or capreomycin, is a stark setback for global TB control. Overburdened public-health systems with inadequate resources for case detection and management and high HIV coinfection rates in many regions have contributed to the emergence of XDR-TB. Patients with XDR-TB have poor outcomes, prolonged infectious periods and limited treatment options. To prevent an epidemic of untreatable XDR-TB, improvements in XDR-TB surveillance, increased laboratory capacity for rapid detection of drug-resistant strains, better infection control and the development of new therapeutics are urgently needed.

AB - Extensively drug-resistant (XDR)-TB, defined as TB with resistance to at least isoniazid, rifampin, a fluoroquinolone and either amikacin, kanamycin or capreomycin, is a stark setback for global TB control. Overburdened public-health systems with inadequate resources for case detection and management and high HIV coinfection rates in many regions have contributed to the emergence of XDR-TB. Patients with XDR-TB have poor outcomes, prolonged infectious periods and limited treatment options. To prevent an epidemic of untreatable XDR-TB, improvements in XDR-TB surveillance, increased laboratory capacity for rapid detection of drug-resistant strains, better infection control and the development of new therapeutics are urgently needed.

KW - Drug-susceptibility testing

KW - Extensively drug-resistant tuberculosis

KW - Multidrug-resistant tuberculosis

KW - Second-line drug

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=55349099511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55349099511&partnerID=8YFLogxK

U2 - 10.1586/14787210.6.5.713

DO - 10.1586/14787210.6.5.713

M3 - Review article

C2 - 18847407

AN - SCOPUS:55349099511

SN - 1478-7210

VL - 6

SP - 713

EP - 724

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

IS - 5

ER -

Extensively drug-resistant tuberculosis: New strains, new challenges

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this